ASCO GU 2019 darolutamide, ARAMIS study darolutamide in non-metastatic castration-resistant prostate (nmCRPC), Karmin Fizazi, MD, the efficacy and safety of ODM-201 in high-risk nmCRPC patients.
— Read on www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110279-sco-gu-2019-efficacy-and-safety-data-of-the-aramis-study-darolutamide-in-nonmetastatic-castration-resistant-prostate-cancer-patients.html
ASCO GU 2019: ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC
ASCO GU 2019 ARCHES trial, metastatic hormone-sensitive prostate cancer (mHSPC), Andrew Armstrong, MD, XTANDI® (enzalutamide) significantly improved radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer, androgen deprivation therapy with enzalutamide or placebo, ENZA plus ADT, improved rPFS.
— Read on www.urotoday.com/conference-highlights/asco-gu-2019/asco-gu-2019-prostate-cancer/110267-asco-gu-2019-phase-3-study-of-androgen-deprivation-therapy-adt-with-enzalutamide-enza-or-placebo-pbo-in-metastatic-hormone-sensitive-prostate-cancer-mhspc-the-arches-trial.html